582,952 Shares in Progyny, Inc. $PGNY Acquired by William Blair Investment Management LLC

William Blair Investment Management LLC bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 582,952 shares of the company’s stock, valued at approximately $16,807,000.

Several other hedge funds and other institutional investors have also bought and sold shares of PGNY. Royal Bank of Canada increased its holdings in shares of Progyny by 384.8% in the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares during the period. Amundi lifted its stake in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after purchasing an additional 5,817 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares in the last quarter. Invesco Ltd. boosted its position in Progyny by 37.4% during the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after purchasing an additional 103,253 shares in the last quarter. Finally, Walleye Capital LLC grew its stake in Progyny by 6.9% in the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after purchasing an additional 780 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Insider Buying and Selling at Progyny

In other news, Director Cheryl Scott sold 7,439 shares of Progyny stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the completion of the transaction, the director directly owned 19,772 shares of the company’s stock, valued at $521,783.08. The trade was a 27.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark S. Livingston sold 2,517 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the completion of the transaction, the chief financial officer owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. This represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 19,063 shares of company stock worth $489,413. 9.90% of the stock is currently owned by insiders.

Progyny Stock Performance

NASDAQ PGNY opened at $25.65 on Friday. The stock has a 50-day simple moving average of $29.13 and a two-hundred day simple moving average of $23.52. The firm has a market capitalization of $1.97 billion, a P/E ratio of 27.88, a PEG ratio of 1.86 and a beta of 1.01. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $33.06.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The firm had revenue of $350.51 million for the quarter, compared to the consensus estimate of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, analysts forecast that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny announced that its board has approved a share buyback plan on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of brokerages have commented on PGNY. Wall Street Zen downgraded shares of Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Canaccord Genuity Group set a $35.00 price objective on shares of Progyny in a research report on Friday, August 7th. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Weiss Ratings upgraded shares of Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 13th. Finally, Bank of America raised their price target on Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.91.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.